You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)

    SBC: NANOHYBRIDS INC            Topic: N

    ABSTRACTThe wet form of age related macular degenerationAMDaccounts forof all AMD related blindness and affectsmillion people withnew cases each year in the USMinimally invasive and selective drug delivery to the eye still remains an open challengethe current standard of care involves delivery of antivascular endothelial growth factoranti VEGFdrugs via intraocular injectionFor patients refractory ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a novel platform for rapid identification of drug targets and anti-targets

    SBC: Truvitech, LLC            Topic: NCATS

    PROJECT SUMMARY Drugs act by altering the activities of particular componentstargetswithin a cell or organismThusdrug discovery campaigns begin by identifying a targetfollowed by screening this target with compounds to identify leads that can be developed into a drugUnfortunatelyidentifying effective drug targets for a given diseaselet alone for individual patientse gin highly heterogeneous cancer ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical Development of 2nd Generation HIV Maturation Inhibitors

    SBC: DFH Pharma, Inc            Topic: 400

    Project SummaryDespite advances in the development of HIV drugs there remains a need for new therapiesToxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antiviralsMaturation inhibitorsMIsrepresent one such class of HIV therapiesHIV maturation inhibitors block virus replication by disrupting the con ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. In Silico Identification of Novel GHB Receptor Ligands for SSADH Deficiency, a Disorder of GABA Metabolism

    SBC: SPERAGEN, INC.            Topic: 102

    Summary The most prevalent inherited disorder of GABA metabolismsuccinic semialdehyde dehydrogenase deficiencySSADHDpresents a non specific neurological phenotype associated with physiological accumulation of the major inhibitory neurotransmitter GABA and the GABAderivativehydroxybutyrateGHBAn absence of targeted therapy for SSADHD underlies this application s rationalePreclinical and clinical stu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Veristride STEP-R: an interactive verbal/auditory gait trainer

    SBC: Veristride, Inc.            Topic: 600

    Veristride IncProject Summary When surveyedof stroke survivors said the ability toget out and aboutis considered between important and essential for a better lifeHoweverthat desire falls short of reality for most stroke survivorsOftenwalking across a neighborhood street or from a car to a home is an insurmountable task with little opportunity for working on improvement in gaitOnce insurance covera ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. In vitro and in vivo evaluation of elephant p53 (EP53) protein nanoparticles for pediatric osteosarcoma

    SBC: Peel Therapeutics, Inc            Topic: 102

    PROJECT SUMMARY ABSTRACT PEEL TherapeuticsIncis a life sciences company created to impact the lives of people with cancerBased on the research efforts of DrJoshua Schiffman and DrAvi SchroederPEEL TherapeuticsPEELhas created liposomal nanoparticles that have been loaded with elephant pEPproteins as a new class of anti cancer protein therapeuticsElephants have an unexpectedly low rate of cancer giv ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid development of a Zika-specific diagnostic test

    SBC: Z-Quick, LLC            Topic: NIAID

    Project Summary Abstract Miami has emerged as the US epicenter of the now global Zika virusZIKVepidemicThe consequences of infection remain to be fully elucidatedbut the probable link between ZIKV infection and fetal developmental complications raises enormous concern as to the potential impact of ZIKVCurrent emergency use authorizationEUAcommercial assays detect ZIKV RNAthe presence of ZIKV speci ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Measuring Infant Pain Objectively using Sensor Fusion and Machine Learning Algorithms

    SBC: AUTONOMOUS HEALTHCARE INC            Topic: R41

    Newborns are routinely and frequently exposed to pain during Neonatal ICUNICUcarePain assessments in neonates are difficultlabor intensivesubjective and unreliableoften resulting in excessive or inadequate analgesiaOur overall objective is to measure infant pain objectivelyreliablyand in real timeWe will extract pain related information from multiple non invasive sensorsdevelop a sensor fusion fra ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government